Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice

Abstract Multiple FDA-approved SARS-CoV-2 vaccines currently provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- and vaccination-induced immunity continue to emerge. I...

Full description

Bibliographic Details
Main Authors: Sonia Jangra, Jeffrey J. Landers, Gabriel Laghlali, Raveen Rathnasinghe, Prajakta Warang, Seok-Chan Park, Jessica. J. O’Konek, Gagandeep Singh, Katarzyna W. Janczak, Adolfo García-Sastre, Nandini Arya, Dilara Karadag, James R. Baker, Michael Schotsaert, Pamela T. Wong
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-023-00691-1

Internet

https://doi.org/10.1038/s41541-023-00691-1

Similar Items